Journal
JOURNAL OF THORACIC ONCOLOGY
Volume 5, Issue 9, Pages 1477-1480Publisher
ELSEVIER SCIENCE INC
DOI: 10.1097/JTO.0b013e3181e981d9
Keywords
EGFR; Erlotinib; Long term; Side effects; Fatigue
Categories
Ask authors/readers for more resources
Introduction: Currently, the inhibitor of the epidermal growth factor receptor tyrosine kinase erlotinib is widely used for the treatment of non-small cell lung: cancer Patients with a mutation or deletion in the epidermal growth factor receptor gene will benefit most and are likely to receive the drug for long periods and willing to accept side effects if responding Methods: Twenty-two cases with prolonged administration of erlotinib (at least 6 months) and side effects are reported Three cases with specific side effects are described in detail Results: In addition to the well-known side effects such as folliculitis and diarrhea, patients reported paronychia, fatigue. and hair changes Discussion: Alter prolonged administration of erlotinib in most patients, the initial side effects persist while other inconvenient ones may develop. This may lead to close reductions or even cessation of treatment
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available